CERELUX, LLC

line
To improve the prognosis of stroke patients by
developing innovative diagnostics and therapies.

ABOUT

Cerelux, LLC’s mission is to improve the prognosis of stroke patients by developing innovative diagnostics and therapies.

Stroke is a very heterogeneous disease and ischemic stroke affects over 700,000 patients every year in the US. Emergent large vessel occlusion (ELVO) is a leading cause of death and disability each year throughout the world, accounting for 30-40% of all ischemic stroke, which equates to around 276,000 patients in the U.S. each year. Stroke also leads to vascular cognitive impairment and dementia (VCID), which occurs in 25-30% of stroke patients. Intravenous t-PA and mechanical thrombectomy (MT, endovascular removal of the thrombus using suction and/or stent-retriever devices) have greatly improved the ability to restore blood flow during a stroke; indeed, thrombectomy improves patient outcomes even if initiated 24 hours after stroke onset. Despite these effective strategies to re-establish blood flow, patients still have significant long-term functional and cognitive deficits, only 17% of patients achieved a normal outcome without any disability. Pre-procedure imaging and successful procedure completion are not reliable to predict patient prognosis and new approaches are needed to predict and improve patient prognosis.

Cerelux, LLC is discovering in-vitro diagnostics and adjuvant therapies by investigating the cellular/molecular events occurring during a stroke in the vicinity of the infarct by accessing samples from stroke patients during mechanical thrombectomy procedures.

GET IN TOUCH

  • This field is for validation purposes and should be left unchanged.